Clinical trials: DAPT(Dual Antiplatelet Therapy)
Acute Coronary Syndrome
DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial
To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of…
- Trial name
- ONE-PASS (NCT05305482)
- Testing
- Drug-coated stent, Drug-eluting stent
- Where
- South Korea
- Volunteers
- 3,520 people
- Sponsor
- Yonsei University
Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI)
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
The study aims to determine the feasibility and clinical utility of incorporating precision medicine approaches, incorporating both cytochrome P450 2C19 (CYP2C19) genotyping and platelet reactivity phenotyping, with standard of…
- Conditions
- Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA)
- Trial name
- NCT04090281
- Testing
- CYP2C19 genotyping
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Southern California
Chronic Total Occlusion of Coronary Artery, Vascular Disease
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-AV DAPT (NCT01106534)
- Testing
- clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
- Where
- 144 sites in United States
- Volunteers
- 870 people
- Sponsor
- Abbott Medical Devices
Noncardioembolic Cerebral Infarction
Cilostazol Stroke Prevention Study for Antiplatelet Combination
To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol (Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for secondary prevention of ischemic stroke in…
- Trial name
- CSPS・com (NCT01995370)
- Testing
- aspirin, clopidogrel, cilostazol
- Where
- Japan
- Volunteers
- 1,884 people
- Sponsor
- Japan Cardiovascular Research Foundation
Acute Coronary Syndrome, Myocardial Infarction
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter
- Trial name
- WOEST-3 (NCT04436978)
- Testing
- 30-day DAPT, Guideline-directed therapy
- Where
- 20 sites in Belgium, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- St. Antonius Hospital
Chronic Coronary Syndrome, Stable Coronary Artery Disease CAD
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
The purpose of this study is to compare the effect of prasugrel plus low-dose aspirin versus high dose aspirin alone (300mg) and versus low dose aspirin alone (75 mg) in patients with chronic coronary disease undergoing coronary…
- Trial name
- OPTIMUS-CABG (NCT07195149)
- Testing
- High-Dose Aspirin 300 mg, DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg), Low-Dose Aspirin 75 mg
- Where
- 18 sites in Poland
- Volunteers
- 1,703 people
- Sponsor
- Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.
Coronary Artery Disease
Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DES
This study is a prospective, open-label, multicenter, randomized clinical trial to evaluate the efficacy of 1 month dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel followed by clopidogrel monotherapy, compared with…
- Trial name
- GENOSS-DAPT (NCT05770674)
- Testing
- 1 Month vs. 12 Months DAPT
- Where
- South Korea
- Volunteers
- 2,186 people
- Sponsor
- Kiyuk Chang
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
The aim of this study is to assess the safety and efficacy of the CYP2C19 genotype-guided abbreviated dual antiplatelet therapy (DAPT) strategy versus the un-guided stepwise intensity de-escalation of DAPT strategy in patients…
- Trial name
- GUIDE-HBR (NCT06763744)
- Testing
- P2Y12 antagonist monotherapy, clopidogrel + aspirin
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Samsung Medical Center
Gastro Intestinal Bleeding, Ischaemic Heart Diseases
Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.
Gastrointestinal bleeding is blood loss in the digestive tract, classified as upper or lower. Ischemic heart disease is due to blocked heart arteries.
- Conditions
- Gastro Intestinal Bleeding, Ischaemic Heart Diseases, Antiplatelet Drugs, Antiplatelet Drug-related Gastrointestinal Injury
- Trial name
- NCT07125651
- Volunteers
- 112 people
- Sponsor
- Assiut University
Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
- Conditions
- Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation), Aspirin, DAPT(Dual Antiplatelet Therapy)
- Trial name
- NCT06007222
- Testing
- Aspirin group, Non-antithrombotic group
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- OCEAN-SHD Study Group
Coronary Artery Disease
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention.
- Trial name
- SWAP-8 (NCT06821191)
- Testing
- clopidogrel 75 mg, Prasugrel 5 mg
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of Florida
ST Elevation Myocardial Infarction
STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT
Primary percutaneous coronary intervention (PCI) is the preferred revascularization strategy for patients with acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- STARS DAPT (NCT05785897)
- Testing
- Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation
- Where
- 2 sites in Switzerland
- Volunteers
- 350 people
- Sponsor
- IGLESIAS Juan Fernando
Stroke, Thrombolysis
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
Rationale and Relevance: Branch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and…
- Conditions
- Stroke, Thrombolysis, DAPT(Dual Antiplatelet Therapy), SAPT(Single Antiplatelet Therapy)
- Trial name
- NCT07299994
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 462 people
- Sponsor
- Sigmund Freud PrivatUniversitat
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Diseases
The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation
The aim of the SPARTA trial is to clarify the impact of extending DAPT beyond 1 year after XINSORB BRS implantation by investigating the balance of risk and benefit in a broad population of treated patients.
- Trial name
- SPARTA (NCT04501900)
- Testing
- Clopidogrel
- Volunteers
- 2,106 people
- Sponsor
- Shanghai Zhongshan Hospital
Coronary Artery Disease, CABG
The 10-Year Extended Follow-up of the DACAB Trial
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial.
- Conditions
- Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass
- Trial name
- DACAB-FE-10Y (NCT07480629)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
High Bleeding Risk Patients, DAPT(Dual Antiplatelet Therapy)
OCT-based DAPT Cessation in HBR Patients
This study investigates whether patients with diabetes mellitus (DM) and a high risk of bleeding can safely stop dual antiplatelet therapy (DAPT) earlier than usual after receiving a special type of stent called a polymer-free…
- Conditions
- High Bleeding Risk Patients, DAPT(Dual Antiplatelet Therapy), Coronary Artery Disease, Diabetes Mellitus
- Trial name
- NCT07238764
- Testing
- Optical Coherence Tomography-based early DAPT discontinuation
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
ST Elevated Myocardial Infarction, Dual Antiplatelet Therapy
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and…
- Trial name
- NCT05491200
- Testing
- Prasugrel based short DAPT, Prasugrel based standard DAPT, OCT guided revascularization
- Where
- 27 sites in Belgium, Czechia and 4 more
- Volunteers
- 1,656 people
- Sponsor
- Research Maatschap Cardiologen Rotterdam Zuid
Bleeding
Evaluation of Platelet Aggregability in the Release of CABG in Patients With ACS With DAPT.
The purpose of this study is to assess platelet aggregability by a "point of care" device (Multiplate®) to decrease the release time for coronary artery bypass graft (CABG ) in patients with acute coronary syndrome (ACS) in use…
- Trial name
- NCT02516267
- Testing
- Multiplate ADP®
- Where
- Brazil
- Volunteers
- 190 people
- Sponsor
- University of Sao Paulo General Hospital
Major Bleeding, Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents
This is a chart review of data on use of antiplatelet (AP) medications for acute coronary syndrome in the ER. Guidelines recommend giving aspirin in the ER and a second AP agent in the cath lab.
- Trial name
- DATES (NCT07039149)
- Where
- 2 sites in Jordan
- Volunteers
- 200 people
- Sponsor
- Jordan Collaborating Cardiology Group